The Common Thread
All four products — Botox, Dysport, Xeomin, and Daxxify — contain botulinum toxin type A. They all work by temporarily blocking nerve signals to muscles, reducing muscle contraction and smoothing wrinkles. Think of them like different car manufacturers: the fundamental technology is the same, but each brand has distinct characteristics in formulation, onset, spread, and duration.
Botox (OnabotulinumtoxinA)
The original and most widely known. Botox has the longest track record (FDA-approved since 2002) and the most extensive clinical data. Onset is typically 3-5 days with full results at 14 days. Duration averages 3-4 months. It's precise and predictable, making it the workhorse of aesthetic medicine. Botox is often the default choice for patients new to neuromodulators.
Dysport (AbobotulinumtoxinA)
Dysport has a slightly different protein formulation that tends to diffuse more broadly than Botox — which can be advantageous for large treatment areas like the forehead. It often has a faster onset (2-3 days) and some studies suggest slightly longer duration for certain patients. Dysport is dosed differently (roughly 2.5-3 Dysport units per 1 Botox unit), so pricing isn't directly comparable unit-for-unit.
Xeomin (IncobotulinumtoxinA)
Xeomin's distinguishing feature is its 'naked' formulation — it contains only the active botulinum toxin without accessory proteins. This theoretically reduces the risk of developing antibodies (resistance) over time. Onset and duration are similar to Botox. Xeomin is sometimes preferred for patients who've developed resistance to Botox or Dysport, or as a preventive choice for long-term users.
Daxxify (DaxibotulinumtoxinA-lanm)
The newest entrant, FDA-approved in 2022. Daxxify's game-changer is duration: it lasts an average of 6 months (some patients report 9 months), compared to 3-4 months for other neuromodulators. It achieves this through a unique peptide formulation that helps the toxin adhere to nerve endings. The trade-off is higher upfront cost per treatment — but for patients who want fewer appointments per year, the per-month value can be comparable.